Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1039-1050

  Tsai, Ping Chiao ^a   Hernandez Ilizaliturri, Francisco J ^a   Bangia, Naveen ^a   Olejniczak, Scott H ^b   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; INTERLEUKIN 4; RITUXIMAB;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CHROMATIN IMMUNOPRECIPITATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE SILENCING; HUMANS; INTERLEUKIN-4; LYMPHOMA, B-CELL; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; RNA STABILITY; RNA, MESSENGER;

EID: 84857082386     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1429     Document Type: Article

References (42)

1. Calvo-Villas JM, Martin A, Conde E, Pascual A, Heras I, Varela R, et al. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann Oncol 2010;21:1891-7.
2. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-90.
3. Dalle S, Dumontet C. [Rituximab: mechanism of action and resistance]. Bull Cancer 2007;94:198-202.
4. Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829-36.
5. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-5. (Pubitemid 29131971)
6. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514-20. (Pubitemid 37419939)
7. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 2005;32:616-21. (Pubitemid 41415090)
8. Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003;70:330-2. (Pubitemid 36560534)
9. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561-70. (Pubitemid 351413941)
10. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008;14:1550-60. (Pubitemid 351413940)
11. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12:4027-35. (Pubitemid 44078090)
12. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Kuniyoshi R, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:2523-30.
13. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201.
14. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600-9. (Pubitemid 43201712)
15. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998;161:3242-8.
16. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995;270:22632-8.
17. Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:2424-36. (Pubitemid 350253475)
18. Mankai A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, et al. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. Cancer Res 2008;68:7512-9.
19. Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997;90:3984-95. (Pubitemid 27484052)
20. Thevenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993;268:5949-56. (Pubitemid 23090931)
21. Thevenin C, Rieckmann P, Kozlow EJ, Kehrl JH. Identification of a diverged octamer binding site important in the B cell-specific expression of the CD20 gene. Trans Assoc Am Physicians 1992;105:15-24.
22. Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000;24:411-5. (Pubitemid 30227241)
23. Kahl BS. Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Lymphoma Myeloma 2006;6:423-6.
24. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866-73. (Pubitemid 38018069)
25. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006;29:388-97. (Pubitemid 44288951)
26. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-81.
27. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, et al. Mouse CD20 expression and function. Int Immunol 2004;16:119-29. (Pubitemid 38054633)
28. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010;120:214-22.
29. Chen YJ, Inouye M. The intramolecular chaperone-mediated protein folding. Curr Opin Struct Biol 2008;18:765-70.
30. Fink AL. Chaperone-mediated protein folding. Physiol Rev 1999;79:425-49. (Pubitemid 29210927)
31. Hartl FU. Principles of chaperone-mediated protein folding. Philos Trans R Soc Lond B Biol Sci 1995;348:107-12.
32. Hubbard TJ, Sander C. The role of heat-shock and chaperone proteins in protein folding: possible molecular mechanisms. Protein Eng 1991;4:711-7.
33. Willardson BM, Howlett AC. Function of phosducin-like proteins in G protein signaling and chaperone-assisted protein folding. Cell Signal 2007;19:2417-27. (Pubitemid 47542295)
34. Pagny S, Cabanes-Macheteau M, Gillikin JW, Leborgne-Castel N, Lerouge P, Boston RS, et al. Protein recycling from the Golgi apparatus to the endoplasmic reticulum in plants and its minor contribution to calreticulin retention. Plant Cell 2000;12:739-56.
35. Stevens TL, Blum JH, Foy SP, Matsuuchi L, DeFranco AL. A mutation of the mu transmembrane that disrupts endoplasmic reticulum retention. Effects on association with accessory proteins and signal transduction. J Immunol 1994;152:4397-406. (Pubitemid 24134397)
36. Guan JL, Machamer CE, Rose JK. Glycosylation allows cell-surface transport of an anchored secretory protein. Cell 1985;42:489-96.
37. Spiliotis ET, Pentcheva T, Edidin M. Probing for membrane domains in the endoplasmic reticulum: retention and degradation of unassembled MHC class I molecules. Mol Biol Cell 2002;13:1566-81. (Pubitemid 34522639)
38. Spiliotis ET, Manley H, Osorio M, Zuniga C, Edidin M. Selective export of MHC class I molecules from the ER after their dissociation from TAP. Immunity 2001;14:205. (Pubitemid 32206522)
39. Venkitaraman AR, Williams GT, Dariavach P, Neuberger MS. The B-cell antigen receptor of the five immunoglobulin classes. Nature 1991;352:777-81. (Pubitemid 21912423)
40. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 2008;283:18545-52.
41. Zhang Q, Salter RD. Distinct patterns of folding and interactions with calnexin and calreticulin in human class IMHC proteins with altered Nglycosylation. J Immunol 1998;160:831-7. (Pubitemid 28049324)
42. Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO J 1994;13:675-82. (Pubitemid 24050682)